[{"orgOrder":0,"company":"Banner Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved","graph3":"Banner Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Delayed Release Capsule","sponsorNew":"Banner Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Banner Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Banner Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved","graph3":"Banner Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Delayed Release Capsule","sponsorNew":"Banner Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Banner Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Banner Life Sciences","sponsor":"Cycle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Monomethyl Fumarate","moa":"Nrf2\/Keap1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Banner Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Banner Life Sciences \/ Cycle Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Banner Life Sciences \/ Cycle Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Banner Life Sciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Cycle Pharmaceuticals acquired Banner, which includes its Bafiertam (monomethyl fumarate) product for the treatment of relapsing forms of multiple sclerosis.

                          Product Name : Bafiertam

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 13, 2025

                          Lead Product(s) : Monomethyl Fumarate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Cycle Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : BAFIERTAM™ , a novel fumarate for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, has commercially launched and is now avai...

                          Product Name : Bafiertam

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 03, 2020

                          Lead Product(s) : Monomethyl Fumarate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : BAFIERTAM™ (monomethyl fumarate), a novel fumarate with a similar profile as Vumerity®, will be commercially available September 1, 2020.

                          Product Name : Bafiertam

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 16, 2020

                          Lead Product(s) : Monomethyl Fumarate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank